Geode Capital Management
ATXI

Geode Capital Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Geode Capital Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-695
Closed -$7.69K – 4633
2024
Q1 		$7.69K Hold
695
– – ﹤0.01% 4569
2023
Q4 		$8.48K Sell
695
-6
-0.9% -$140 ﹤0.01% 4602
2023
Q3 		$37K Hold
701
– – ﹤0.01% 4494
2023
Q2 		$60.5K Buy
701
+549
+361% +$45.2K ﹤0.01% 4465
2023
Q1 		$13.4K Sell
152
-2
-1% -$185 ﹤0.01% 4747
2022
Q4 		$13K Buy
+154
New +$27.9K ﹤0.01% 4822
2022
Q3 		– Sell
-75
Closed -$22K – 5048
2022
Q2 		$22K Hold
75
– – ﹤0.01% 4911
2022
Q1 		$40K Buy
75
+6
+9% +$4.49K ﹤0.01% 4849
2021
Q4 		$70K Sell
69
-6
-8% -$8.68K ﹤0.01% 4807
2021
Q3 		$125K Buy
75
+4
+6% +$8.27K ﹤0.01% 4611
2021
Q2 		$199K Sell
71
-47
-40% -$232K ﹤0.01% 4344
2021
Q1 		$804K Buy
118
+7
+6% +$48.1K ﹤0.01% 3648
2020
Q4 		$745K Buy
111
+7
+7% +$36.7K ﹤0.01% 3458
2020
Q3 		$1.27M Hold
104
– – ﹤0.01% 3118
2020
Q2 		$1.26M Buy
104
+42
+68% +$474K ﹤0.01% 3070
2020
Q1 		$626K Buy
62
+2
+3% +$20K ﹤0.01% 3202
2019
Q4 		$651K Hold
60
– – ﹤0.01% 3419
2019
Q3 		$404K Hold
60
– – ﹤0.01% 3542
2019
Q2 		$427K Buy
+60
New +$347K ﹤0.01% 3524

Other funds holding ATXI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management's ATXI Position: Q2 2024 in Review

Geode Capital Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 695 shares — an estimated $7.69K sold.

Geode Capital Management first reported a position in ATXI in Q2 2019 and held it in 19 quarters. The position peaked at $1.27M in Q3 2020. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

  • Geode Capital Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 695 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $7.69K.
  • Geode Capital Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Geode Capital Management's Avenue Therapeutics, Inc. Common Stock position peaked at $1.27M in Q3 2020.
  • 9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.